These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 33271423

  • 1. Prognosis of HER2-positive pregnancy-associated breast cancer: Analysis from the French CALG (Cancer Associé à La Grossesse) network.
    Boudy AS, Ferrier C, Selleret L, Zilberman S, Arfi A, Sussfeld J, Gligorov J, Richard S, Bendifallah S, Chabbert-Buffet N, Touboul C, Daraï E.
    Breast; 2020 Dec; 54():311-318. PubMed ID: 33271423
    [Abstract] [Full Text] [Related]

  • 2. Propensity score to evaluate prognosis in pregnancy-associated breast cancer: Analysis from a French cancer network.
    Boudy AS, Naoura I, Selleret L, Zilberman S, Gligorov J, Richard S, Thomassin-Naggara I, Chabbert-Buffet N, Ballester M, Bendifallah S, Darai E.
    Breast; 2018 Aug; 40():10-15. PubMed ID: 29665447
    [Abstract] [Full Text] [Related]

  • 3. [Clues to differentiate pregnancy-associated breast cancer from those diagnosed in postpartum period: A monocentric experience of pregnancy-associated cancer network (CALG)].
    Boudy AS, Naoura I, Zilberman S, Gligorov J, Chabbert-Buffet N, Ballester M, Selleret L, Darai E.
    Bull Cancer; 2017 Jun; 104(6):574-584. PubMed ID: 28477874
    [Abstract] [Full Text] [Related]

  • 4. 5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.
    Ploquin A, Pistilli B, Tresch E, Frenel JS, Lerebours F, Lesur A, Loustalot C, Bachelot T, Provansal M, Ferrero JM, Coussy F, Debled M, Kerbrat P, Vinceneux A, Allouache D, Morvan F, Dalenc F, Guiu S, Rouzier R, Vanlemmens L.
    Eur J Cancer; 2018 May; 95():30-37. PubMed ID: 29625257
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [Abstract] [Full Text] [Related]

  • 10. Association with pregnancy increases the risk of local recurrence but does not impact overall survival in breast cancer: A case-control study of 87 cases.
    Genin AS, De Rycke Y, Stevens D, Donnadieu A, Langer A, Rouzier R, Lerebours F.
    Breast; 2016 Dec; 30():222-227. PubMed ID: 26456897
    [Abstract] [Full Text] [Related]

  • 11. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
    Zhang Y, Mo M, Li JW, Zhou Y, Wu J, Yu KD, Shen ZZ, Shao ZM, Liu GY.
    Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
    [Abstract] [Full Text] [Related]

  • 12. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
    Al-Hilli Z, Hieken TJ, Hoskin TL, Heins CN, Boughey JC.
    J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
    [Abstract] [Full Text] [Related]

  • 13. Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses.
    Myller S, Ipatti P, Jääskeläinen A, Haapasaari KM, Jukkola A, Karihtala P.
    Acta Oncol; 2020 Sep; 59(9):1036-1042. PubMed ID: 32394761
    [Abstract] [Full Text] [Related]

  • 14. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
    Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber RD, de Azambuja E, Ignatiadis M.
    Cancer; 2019 Jan 15; 125(2):307-316. PubMed ID: 30335191
    [Abstract] [Full Text] [Related]

  • 15. The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study.
    Azim HA, Botteri E, Renne G, Dell'orto P, Rotmensz N, Gentilini O, Sangalli C, Pruneri G, Di Nubila B, Locatelli M, Sotiriou C, Piccart M, Goldhirsch A, Viale G, Peccatori FA.
    Acta Oncol; 2012 May 15; 51(5):653-61. PubMed ID: 22171586
    [Abstract] [Full Text] [Related]

  • 16. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA, Pilewskie M, Patil S, Barrio AV, Stempel M, Wen HY, Morrow M.
    Ann Surg Oncol; 2017 Sep 15; 24(9):2556-2562. PubMed ID: 28560596
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Oncological management of pregnancy-associated cancers: analysis from the French CALG (Cancer Associé à La Grossesse) network.
    Boudy AS, Zaccarini F, Selleret L, Arfi A, Guiggi I, Touboul C, Bendifallah S, Darai E.
    Acta Oncol; 2020 Sep 15; 59(9):1043-1050. PubMed ID: 32525429
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.